Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
100%
Paroxysmal Nocturnal Hemoglobinuria
76%
Rivaroxaban
63%
Thromboembolism
50%
Prospective Study
50%
Direct Oral Anticoagulant
49%
Antivitamin K
47%
Bleeding
40%
Dabigatran
38%
Adverse Drug Reaction
31%
Pathophysiology
30%
Eculizumab
30%
Drug Concentration
29%
Thrombosis
25%
Cohort Study
25%
Atrial Fibrillation
25%
Daboia russellii
25%
Dabigatran Etexilate
25%
Viper Venom
25%
Clinical Study
25%
Procoagulant
25%
Diseases
18%
Toxic Injury
17%
Drug Interaction
15%
Hemolysis
13%
Apixaban
12%
Drug Approval
12%
Ensure
12%
Prevalence
12%
Pharmacodynamics
11%
Drug
11%
Kidney Failure
11%
Thrombin
11%
Vein Thrombosis
10%
Artery Thrombosis
10%
Phospholipid
8%
Cause of Death
7%
Flow Cytometry
7%
Emergency
6%
Transient Ischemic Attack
6%
Adverse Event
6%
Acute Kidney Failure
5%
Pharmacokinetics
5%
Brain Hemorrhage
5%
Gastrointestinal Hemorrhage
5%
Complication
5%
Hypertension
5%
Life Expectancy
5%
Myelodysplastic Syndrome
5%
Infection
5%
Medicine and Dentistry
Paroxysmal Nocturnal Hemoglobinuria
50%
Erythrocyte Concentrate
50%
Diagnosis
50%
Procoagulant
47%
Assay
38%
Therapeutic Procedure
30%
Pathophysiology
30%
Microparticle
25%
Thromboplastin
25%
Thrombosis
25%
Membrane Microparticle
25%
Platelet Microparticle
25%
Heparin-Induced Thrombocytopenia
25%
Cells
25%
Heparin
25%
Patient
22%
Thrombin
20%
Erythrocyte
17%
Phospholipid
14%
Hemolysis
14%
Acute Promyelocytic Leukemia
12%
Venous Thromboembolism
12%
Serotonin Release
11%
Release Assay
11%
Transfusion
10%
Phlebothrombosis
10%
Hematopoietic Stem Cell
10%
Prophylaxis
10%
Acquired Disorder
10%
Patient Experience
10%
Artery Thrombosis
10%
Complication
9%
Flow Cytometry
9%
Disseminated Intravascular Coagulation
6%
Leukemia Cell
6%
Laboratory
5%
Monocyte
5%
Smooth Muscle
5%
Renal Failure
5%
Cause of Death
5%
Analysis
5%
Pulmonary Hypertension
5%
Hypertension
5%
Infection
5%
Donor
5%
In Vitro
5%
Disease
5%
Kidney Function
5%
Dystonia
5%
Aplastic Anemia
5%
Nursing and Health Professions
Sample
33%
Time
31%
Anticoagulant Agent
27%
Eculizumab
25%
Anticoagulation
25%
Heparin Induced Thrombocytopenia
25%
Dabigatran
25%
Thrombin
25%
Viper Venom
25%
Cohort Analysis
25%
Rivaroxaban
25%
Erythrocyte Concentrate
25%
Patient
25%
Paroxysmal Nocturnal Hemoglobinuria
25%
Pathophysiology
25%
Antivitamin K
21%
Analyzer
19%
Clinical Outcome
14%
Combination Therapy
12%
Release Assay
11%
Serotonin
11%
Procoagulant
9%
Thrombocyte Free Plasma
9%
Blood Level
8%
Liquid Chromatography-Mass Spectrometry
8%
Trough Concentration
8%
Flow Cytometry
6%
Low Molecular Weight Heparin
6%
Laboratory
6%
Standardization
6%
Parameters
6%
Reproducibility
6%
Experiment
6%
Control
6%
Temperature
6%
Erythrocyte Preservation
5%
